Medication adherence among transgender women living with HIV
Medication adherence among transgender women living with HIV
复制标题
DOI：
10.1080/09540121.2016.1146401
复制
发表时间：
2016-08-01
影响因子：
1.7
通讯作者：
Lee, Kathryn A.
中科院分区：
文献类型：
--
作者：
Baguso, Glenda N.;Gay, Caryl L.;Lee, Kathryn A.
药物依从性与艾滋病毒感染成人的健康结果相关。美国感染艾滋病毒的跨性别女性 (TWLWH) 报告称，她们对药物的依从性不佳，并且很难将艾滋病毒药物纳入她们的日常生活，但很少有研究探讨与跨性别女性的药物依从性相关的因素。因此，本文的目的是研究与跨性别女性自我报告的药物依从性相关的人口统计学和临床因素。这项二次分析基于症状和遗传研究收集的数据，其中包括在北加州招募的 22 名自我认定的跨性别女性、201 名非跨性别男性和 72 名非跨性别女性的方便样本。使用艾滋病临床试验组依从性问卷评估自我报告的药物依从性。评估了人口统计学和临床变量的性别差异，以及报告高依从性和低依从性的跨性别女性之间的差异。与非跨性别男性和非跨性别女性相比，跨性别女性对药物的依从性较低 (p=.028)，并且实现病毒抑制的可能性较小 (p=.039)。在跨性别群体中，黑人/非裔美国人比白人/白种人或其他种族的参与者表现出更好的依从性 (p=.009)。跨性别女性的依从性与药物数量和雌激素治疗无关，但与其他关于整个艾滋病毒人群的报告一致；与低依从性的跨性别女性相比，高依从性的跨性别女性更有可能实现病毒抑制。尽管跨性别人群中艾滋病毒感染率很高，但很少有研究关注 TWLWH，无论是关于他们对抗逆转录病毒治疗的依从性还是他们的总体医疗保健。为了解决持续存在的健康差异，需要更多的研究关注跨性别人群在艾滋病毒治疗中的持续护理。
Medication adherence is linked to health outcomes among adults with HIV infection. Transgender women living with HIV (TWLWH) in the US report suboptimal adherence to medications and are found to have difficulty integrating HIV medication into their daily routine, but few studies explore the factors associated with medication adherence among transgender women. Thus, the purpose of this paper is to examine demographic and clinical factors related to self-reported medication adherence among transgender women. This secondary analysis is based on data collected from the Symptom and Genetic Study that included a convenience sample of 22 self-identified transgender women, 201 non-transgender men, and 72 non-transgender women recruited in northern California. Self-reported medication adherence was assessed using the AIDS Clinical Trials Group Adherence Questionnaire. Gender differences in demographic and clinical variables were assessed, as were differences between transgender women reporting high and low adherence. Transgender women had lower adherence to medications compared to non-transgender males and non-transgender females (p=.028) and were less likely to achieve viral suppression (p=.039). Within the transgender group, Black/African-Americans reported better adherence than participants who were Whites/Caucasian or other races (p=.009). Adherence among transgender women was unrelated to medication count and estrogen therapy, but consistent with other reports on the HIV population as a whole; transgender women with high adherence were more likely to achieve viral suppression compared to the transgender women with low adherence. Despite the high incidence of HIV infection in the transgender population, few studies focus on TWLWH, either in regard to their adherence to antiretroviral therapies or to their healthcare in general. To address ongoing health disparities, more studies are needed focusing on the transgender population's continuum of care in HIV therapies.